Mega Lifesciences reported strong Q1 2026 results, with EPS of 0.69, surpassing analyst estimates. Revenue reached 3.41 billion Thai Baht, up 14.4% year-over-year.
Following the announcement, the stock price rose 2.82% to close at 36.5, reflecting investor confidence.












